Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1Not yet recruiting 1Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Lymphoma, Non-Hodgkin 1Leukemia, Lymphocytic, Chronic, B-Cell 1

Interventions

Rituximab 21Cyclophosphamide 21fludarabine 12fludarabine phosphate 10pirtobrutinib 6obinutuzumab 6ibrutinib 6acalabrutinib 6Tacrolimus 6Mycophenolic Acid 6Melphalan 6Magnetic Resonance Spectroscopy 6Biopsy 6venetoclax 5tocilizumab 5X-Rays 5Whole-Body Irradiation 5Specimen Handling 5Prednisone 5Phantoms, Imaging 5Peripheral Blood Stem Cell Transplantation 5Nuclear Medicine Department, Hospital 5Etoposide 5Doxorubicin 5Thiotepa 4Lenalidomide 4Granulocyte Colony-Stimulating Factor 4Filgrastim 4Cytarabine 4Bendamustine Hydrochloride 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Lymphoma, Non-Hodgkin × Lisaftoclax × Clear all
NCT03913949 2026-05-01

A Study to Evaluate the Safety,PK and PD of APG-2575 in Patients With Hematologic Malignancies

Ascentage Pharma Group Inc.

Phase 1 Active not recruiting
74 enrolled
LymphoidOther hematologic neoplasm

Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡